{"product_id":"ipamorelin-1","title":"Ipamorelin","description":"\u003cdiv class=\"prod-section\"\u003e \u003cdiv class=\"prod-section-label\"\u003e \u003ci class=\"ti ti-file-description\"\u003e\u003c\/i\u003eResearch Background \u003c\/div\u003e \u003cp class=\"prod-para\"\u003e Ipamorelin is a selective pentapeptide GHS-R1a (ghrelin receptor) agonist (CAS 170851-70-4; MW 711.9 g\/mol) that functions through Ca2+\/IP3 signaling pathways. It represents the most selective growth hormone-releasing peptide (GHRP) available for clean GH secretagogue research, as it does not stimulate ACTH, cortisol, or prolactin at research concentrations. \u003c\/p\u003e \u003cp class=\"prod-para\"\u003e As a fifth-generation GHRP, Ipamorelin demonstrates exceptional receptor selectivity, binding specifically to the ghrelin receptor (GHS-R1a) on pituitary somatotroph cells without off-target effects on other hormonal axes. This selectivity profile distinguishes it from earlier-generation GHRPs that often caused unwanted elevations in cortisol, prolactin, or ACTH, making Ipamorelin the preferred research tool for isolating GH-specific effects. \u003c\/p\u003e \u003cp class=\"prod-para\"\u003e The pentapeptide structure (Aib-His-D-2-Me-Trp-Phe-Lys-NH2) mimics the endogenous ghrelin hormone while providing enhanced metabolic stability and receptor binding affinity. Upon binding to GHS-R1a, Ipamorelin triggers intracellular calcium release and inositol trisphosphate (IP3) signaling, resulting in pulsatile growth hormone release from pituitary stores. \u003c\/p\u003e \u003cp class=\"prod-para\"\u003e In research applications, Ipamorelin demonstrates synergistic effects when combined with GHRH analogs like CJC-1295, as they activate complementary pathways — GHRH increases cAMP while GHS-R1a agonists increase intracellular calcium, together producing supra-additive GH release. This makes it particularly valuable for studies examining GH axis function, body composition, metabolic regulation, and age-related endocrine changes. \u003c\/p\u003e \u003c\/div\u003e \u003cdiv class=\"prod-section\"\u003e \u003cdiv class=\"prod-section-label\"\u003e \u003ci class=\"ti ti-atom\"\u003e\u003c\/i\u003ePhysicochemical Data \u003c\/div\u003e \u003cdiv class=\"table-scroll\"\u003e \u003ctable class=\"prod-table\"\u003e \u003cthead\u003e \u003ctr\u003e \u003cth\u003eCompound\u003c\/th\u003e \u003cth\u003eMW \/ Formula\u003c\/th\u003e \u003cth\u003eCAS No.\u003c\/th\u003e \u003cth\u003eSequence \/ Structure\u003c\/th\u003e \u003cth\u003eReceptor \/ Target\u003c\/th\u003e \u003c\/tr\u003e \u003c\/thead\u003e \u003ctbody\u003e \u003ctr class=\"row-alt\"\u003e \u003ctd class=\"td-bold\"\u003eIpamorelin\u003c\/td\u003e \u003ctd\u003eC38H49N9O5 \/ 711.9 g\/mol\u003c\/td\u003e \u003ctd\u003e170851-70-4\u003c\/td\u003e \u003ctd\u003ePentapeptide ghrelin mimetic\u003c\/td\u003e \u003ctd\u003eGHS-R1a agonist; no ACTH\/cortisol stimulation\u003c\/td\u003e \u003c\/tr\u003e \u003c\/tbody\u003e \u003c\/table\u003e \u003c\/div\u003e \u003c\/div\u003e","brand":"General Peptide","offers":[{"title":"1 Vial","offer_id":50856778793207,"sku":null,"price":24.0,"currency_code":"USD","in_stock":true},{"title":"3 Vials","offer_id":50856778825975,"sku":null,"price":65.0,"currency_code":"USD","in_stock":true},{"title":"5 Vials","offer_id":50856778858743,"sku":null,"price":96.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0934\/1485\/0807\/files\/Endocrine-GH_Ipamorelin.jpg?v=1781176997","url":"https:\/\/generalpeptide.com\/products\/ipamorelin-1","provider":"General Peptide","version":"1.0","type":"link"}